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,A,rmexin I (lipocortin I) and uteroglobin are proteins which have been.re_ported to have an inhibitory effeit on phospholipase A, (PLA,). Annexin I is a member of a fariily of at least eight different proteins which are known to bind io lipid membranes in a Ca2*-dependent manner [1] . It has b6en suggested that the mechanism of annexin inhibitorv action is by direct protein-protein interaction [2] although-Davidson et al. [3] reported thar annexin II (lipoiortin tr) and annexin I rnhlbit porcine pancreatic pl-A, (pPI-A.r) in the presence of 9ut* by substrate sequestration. In botii cases [i, 3] inhibition was completely overcome at higher substrate concentrations. Annexin I also inhibited partially purified preparations of two intracellular PI-Ars isolated flom raf fivtr mitochondria and rat platelets, but again the inhibition decreased with increasing substrate concentration [4, 5] . From these results it was implied that annexin I interacts with the substrate rather than with the enzyme. Uteroglobin, a progesterone-binding protein with some claimed structuial lgTgtogy with PI-A., . [6] has been shown to have pLA2 inhibitory properties [7] by binding directly to the enzyme.
More recently, experiments with synthetic oligopeptides corresponding to a region of purportedly high-s-equence similarity between annexin I (residues-2q6-254\ and uteroglobin (the nine C-terminal amino acid of a c-helix 3) showed.that these peptides have potent pI-A, inhibitory activity in vitro and anti-inflammatory effects lre dvo [8] . Th-e authors sue€esred that the inhibitory effect of the peptide was executed through an interaction with the enzyme rather than with the substrate. However, van Binsbergen-et al. [9] ,n a number of different PLA, assays in vitro have found-no evidence for inhibition by these peptides, either by preincubation with the enzyme or by direct interaction with phospholipids.
Here we use a lipid-monolayer system similar to that described by Verger et al.[l}l to examine both the abilitv of synthetic nonapeptides from annexin I and uteroglobin to interact with_ a lipid monolayer and to inhibit ft-t, tipiA hydrolysis. Synthetic peptides from annexin I, reiidues 246-254 (HDMNKVLDL), and from uteroglobin, residues 39-47 (MQMKKVLDS), as described ab5ve, were svnthesized using a standard Fmoc solid phase approach withan automated synthesizer [11] and their sequences confirmed by amino acid sequence analysis.
Lipid monolayer experiments were performed to see whether the _peptides were able to penetrate the lipid substrate, 1,2-didodecanoyl-sn-glycero-phosphorylcholine, as judged by their ability io cais-e an in".eise in surface pressure of the lipid monolayer at constant surface area. The Tnexq I peptide was incorporated into the lipid film as ghgwn by the increase in surface pressure (Fig.-la) of the lipid monolayer. The pressure at which the peptide was unable to penetrate the lipid film (critical surfa-ce-pressure) was determined by extrapolating to zero surface pressure -(b)
Enzymic velocity measured using a 15 mN/m lipid monolayer after injection of 28 ng of porcine PPI-A2 in the absence (-) and presence of the above peptides. The lipid monolayer used was 1,2-didodecanoyl-sn-glycero-phoiphorylcholine and the buffer was 100 mrvr{ris-HCl, pH 8.0, iontaining 20 mu-NaCl and 1 mr,a-CaClr.
increase and is 28 mN/m. In the case of the uteroglobin peptide no increase in surface pressure was detected. Further studies showed that the presence of the annexin I peplqg i" the lipid monolayer acted to inhibit the activity -of PPLA2 when the surface pressure of the film did not exieed 28 mNlm. Above this pressure the peptide no longer penetrated the lipid and inhibition of the enzyme could nbt be detected (data not shown).
__F-y-ig velocity measurements were made by injecting PPI-A2 under the lipid monolayer and recording ihe rate oI substrate hydrolysis as measured by the decrease in surface area at constant surface pressure, in the presence or absence of peptide (Fig. 1b) . Enzymic velocity depended on the amount of enzyme at the interface and was seen to increase with time until it seemed to approach an asymptotic limit. In the absence of peptide the enzymic velocity at a lipid surface pressure.of 15 mN/m was 11 mm/min per pg protein injected (0.30 nr'a). Preincubation of 0.5 me of the annexin I peptide (4.0 pu) with the lipid monolafer resulted in a reduced enzymic velocity (7 mm/min per pg ppI-A.2). However, no reduction in velocity was detected when the uteroglobin peptide was used (Fig. lb) i.e. there was no detectable inhibition.
In conclusion, we have demonstrated that there is a difference in the way that the above two synthetic peptides interact with lipid films. One of them (from annexin i) was able to penetrate the lipid monolayer at pressures up to 28 mN/m, whilst the peptide from uteroglobin did noi. Furthermore, using an enzyme kinetic assay we have shown that the annexin I synthetic peptide inhibited PPI-A2 activity at a monolayer gurface pressure of 15 mN/m, whilst the peptide from uteroglobin had no significant inhibitory activity.
. ,TL" above findings support those of van Binsbergen et al. [9] . These authors also tested the two nonapepltides as inhibitors of PP[A, and did not find inhibition ai monolaver surface pressures of 30 mN/m. We have shown that wlien there is penetration of the lipid film as in the case of the Corticosteroids are potent anti-inflammatory drugs frequently used in the treatment of inflammation and disease. Their mode of action is multifactoral but in general requires th-e transcription of specific genes and subse{uent formation of new proteins. One such steroid-inducible protein is lipocortin-1. Lipocortin-1 inhibits phospholipase A, activity in assays in vitro and thus supresses the generation of phospholipid-derived inflammatory mediatols, including prostaglandins, leukotrienes and thromboxanes. Studies ln vivo have shown that purified lipocortin-l is able to inhibit both cytokine-induced fever and thermogenesis [l] and carraggenan-induced paw oedema [2] . We have recently published data suggesting a role for lipocortin-l in the central effects of glucocorticoids [ 1 ] . Intracerebroventricular injection in conscious rats of a specific antiserum raised to a lipocortin-l fragment antagonized the suppressive action of dexamethasone on interleukin-lB-induced thermogenesis and pyrogenesis. Recent immunohistochemical studies have demonstrated lipocortin-l immunoreactivity in both normal ald malignant human brain tissue [3] and rat peripheral tissues, but not in rat brain [a] . We have therefore undertaken an immunohistochemical study investigating the distribution of lipocortin-1 in normal rat brain, using a specific antiserum raised in rabbit to amino acids 1-188 of human lipocortin-1. Preliminary experiments have demonstrated -that this antibody can recognize rat hypothalamic lipocortin-l (F. Carey, R. Forder, N. Rothwell & P. Strijbos, unpublished work). Immunoreactive lipocortin-l was visualized using a fluorescent isothiocyanate{abelled goat anti-rabbit antibody. Extensive lipocortin-l immunostaining was observed in ependymal cells lining the lateral and third ventricle. Certain circumventricular organs, e.g. subcommisural organ, subfornical organ and the organum vasculosum of the lamina terminalis, contain specialized ependymocytes, and stained heavily for lipocortin-I . Another population of lipocortin-1-positive specialized ependymocytes is located in the floor and wall of the third ventricle. This population is called tanycytes (for review see [5] ). Of these, only the lateral tanycytes are lipocortin-1 positive. The apical pole of these elongated cells contact the third ventricle and their processes arch ventrolaterally. They make contacts with capillaries and certain neuronal cells within the ventromedial hypothalamus, and with the capillary plexus in the lateral part of the median eminence. The topography and morphology of these lipocortin-l irnmunoreactive tanycytes suggests that they enable blood-cerebrospinal fluid contact, although the role of lipocortin in these secretory processes remains unknown. In addition, a network of varicose fibres was found in the median eminence indicating that certain neurons may contain immunoreactive lipocortin-l. A low density of positive varicose fibers can be observed throughout the brain. Incidental positive staining cell bodies are present in the ventral hypothalamus. Lipocortin-l immunoreactivity was also observed in pyramidal cells in the CA, and CA, regions of the hippocampus. This pattern showed similarities to the pattern of distribution of the interleukin-I, glucocorticoid and nerve growth factor receptor.
The present study has demonstrated lipocortin-1 immunoreactivity in distinct cells of normal rat brain and suggests that lipocortin-l may participate in the secretory processes of tanycytes. Furthermore, its localization in nerve terminals suggest that lipocortin-1 may act as a signal protein
